Additionally, armored CAR-T cells expressing costimulatory ligands (e.g., 4-1BBL, CD40L) or targeting multiple antigens through dual CAR constructs are being explored to improve tumor recognition and reduce relapse rates.[90]. Here, CD40LG is linked to neoplasm.